These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32727899)

  • 21. Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis.
    Kedashiro S; Sugiura A; Mizutani K; Takai Y
    Sci Rep; 2019 Dec; 9(1):18997. PubMed ID: 31831814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
    Lu S; Yu Y; Li Z; Yu R; Wu X; Bao H; Ding Y; Shao YW; Jian H
    J Thorac Oncol; 2019 Apr; 14(4):732-736. PubMed ID: 30610926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung cancer: intragenic ERBB2 kinase mutations in tumours.
    Stephens P; Hunter C; Bignell G; Edkins S; Davies H; Teague J; Stevens C; O'Meara S; Smith R; Parker A; Barthorpe A; Blow M; Brackenbury L; Butler A; Clarke O; Cole J; Dicks E; Dike A; Drozd A; Edwards K; Forbes S; Foster R; Gray K; Greenman C; Halliday K; Hills K; Kosmidou V; Lugg R; Menzies A; Perry J; Petty R; Raine K; Ratford L; Shepherd R; Small A; Stephens Y; Tofts C; Varian J; West S; Widaa S; Yates A; Brasseur F; Cooper CS; Flanagan AM; Knowles M; Leung SY; Louis DN; Looijenga LH; Malkowicz B; Pierotti MA; Teh B; Chenevix-Trench G; Weber BL; Yuen ST; Harris G; Goldstraw P; Nicholson AG; Futreal PA; Wooster R; Stratton MR
    Nature; 2004 Sep; 431(7008):525-6. PubMed ID: 15457249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
    Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
    Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of
    Subramanian J; Katta A; Masood A; Vudem DR; Kancha RK
    Oncologist; 2019 Dec; 24(12):e1303-e1314. PubMed ID: 31292270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines.
    Krishnaswamy S; Bukhari I; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
    Gene; 2018 Dec; 679():335-340. PubMed ID: 30223007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative splicing enriched cDNA libraries identify breast cancer-associated transcripts.
    Ferreira EN; Rangel MC; Galante PF; de Souza JE; Molina GC; de Souza SJ; Carraro DM
    BMC Genomics; 2010 Dec; 11 Suppl 5(Suppl 5):S4. PubMed ID: 21210970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.
    Paulson AK; Linklater ES; Berghuis BD; App CA; Oostendorp LD; Paulson JE; Pettinga JE; Melnik MK; Vande Woude GF; Graveel CR
    Mol Cancer Res; 2013 Sep; 11(9):1112-21. PubMed ID: 23825050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
    Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
    Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas.
    López-Malpartida AV; Ludeña MD; Varela G; García Pichel J
    Lung Cancer; 2009 Jul; 65(1):25-33. PubMed ID: 19046792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
    Peters S; Curioni-Fontecedro A; Nechushtan H; Shih JY; Liao WY; Gautschi O; Spataro V; Unk M; Yang JC; Lorence RM; Carrière P; Cseh A; Chang GC
    J Thorac Oncol; 2018 Dec; 13(12):1897-1905. PubMed ID: 30096481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer.
    Kitamura T; Srivastava J; DiGiovanni J; Kiguchi K
    Mol Carcinog; 2015 Jun; 54(6):459-72. PubMed ID: 24839254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.
    Anastasi S; Sala G; Huiping C; Caprini E; Russo G; Iacovelli S; Lucini F; Ingvarsson S; Segatto O
    Oncogene; 2005 Jun; 24(28):4540-8. PubMed ID: 15856022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer.
    Kristiansen G; Yu Y; Petersen S; Kaufmann O; Schlüns K; Dietel M; Petersen I
    Eur J Cancer; 2001 Jun; 37(9):1089-95. PubMed ID: 11378338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
    Suzawa K; Toyooka S; Sakaguchi M; Morita M; Yamamoto H; Tomida S; Ohtsuka T; Watanabe M; Hashida S; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S
    Cancer Sci; 2016 Jan; 107(1):45-52. PubMed ID: 26545934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
    Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
    Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.